Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 23 of 24 for:    Porphyrins

Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphine (TCPP) for Detection of Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02388074
Recruitment Status : Completed
First Posted : March 13, 2015
Results First Posted : June 17, 2015
Last Update Posted : July 14, 2015
Sponsor:
Collaborator:
Radiology Associates of Albuquerque
Information provided by (Responsible Party):
bioAffinity Technologies Inc.

Brief Summary:
This is a single center study to assess the efficacy of CyPath® Early Detection Lung Cancer Assay to detect lung cancer cells from deep lung sputum.

Condition or disease Intervention/treatment Phase
Lung Cancer Device: CyPath® Not Applicable

Detailed Description:

Meso Tetra (4-Carboxyphenyl) Porphine (TCPP) is a porphyrin that can label cancer cells by reacting to the increased number of low-density lipoproteins coating the surface of cancer cells and the porous nature of the cancer cell membrane, causing the cell to fluoresce under specific wavelengths of light. The primary objective of this clinical trial is to determine the the presence or absence of red fluorescent [ie, cancer] cells (RFCs) from deep-lung sputum samples using the CyPath® Early Lung Cancer Detection Assay from one cohort of Participants who are healthy. The results from this trial will be compared with two additional cohorts of Participants including individuals at high risk for lung cancer and individuals diagnosed with lung cancer. Collection of the sputum samples from high-risk individuals and lung cancer patients is complete (NCT00894127).

Participants who satisfy the inclusion/exclusion criteria will be enrolled into the study and assigned to the healthy cohort. The sputum samples will be collected at the study site or at the Participant's home after explanation of the collection procedure by study staff. Samples will be identified with an identification number blinding the sample identity. Each subject's sputum specimen will be processed onto 13 microscope slides at the University of Texas Health Science Center of San Antonio (UTHSCSA) Laboratory. The UTHSCSA laboratory will process each sputum sample onto slides using the ThinPrep T2000 processor for use in the CyPath® Early Lung Cancer Detection Assay.

Twelve slides from each sputum sample will be labeled with CyPath®. One slide will be used to preform PAP staining for the presence of macrophages. Macrophages are an indication that the sputum sample is from deep within the lungs. A cytopathologist will review the slide and record results on a specimen adequacy form. bioAffinity researchers who will be blinded as to the Participant's identity will perform the CyPath® labeling and scoring of the slides. The study results of the healthy cohort will be used for comparison with the results of a closed study in which the sputum from individuals at high risk of lung cancer and individuals diagnosed with lung cancer was compared.

Findings of the CyPath® assay will not be used in the diagnosis or treatment of Participants.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 25 participants
Intervention Model: Single Group Assignment
Masking: Single (Investigator)
Primary Purpose: Diagnostic
Official Title: Sputum Labeling Utilizing Synthetic Meso Tetra (4-Carboxyphenyl) Porphine (TCPP) for Detection of Lung Cancer
Study Start Date : March 2015
Actual Primary Completion Date : April 2015
Actual Study Completion Date : April 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Arm Intervention/treatment
Experimental: CyPath® Assay of Deep-Lung Sputum Sample
Deep-lung sputum was obtained from healthy individuals who had no known lung disease, was labeled with TCPP and evaluated to detect red fluorescent [ie, cancer] cells (RFCs) from deep-lung sputum samples.
Device: CyPath®
CyPath® diagnostic assay for the early detection of lung cancer using sputum




Primary Outcome Measures :
  1. Number of Red Fluorescent [i.e., Cancer] Cells (RFCs) in Sputum From Healthy Participants [ Time Frame: 2 months ]

    The presence or absence of red fluorescent (RFCs) cancer cells was evaluated in sputum samples from healthy individuals labeled with CyPath®.

    Testing for the study was performed at one study center to collect sputum samples from healthy individuals who have no known lung disease. Comparison of sputum specimens from one cohort of Participants who are healthy with two additional cohorts of Participants, including individuals at high risk for lung cancer and individuals diagnosed with lung cancer, that has already been completed.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Participants who have never smoked nor have known lung diseases

Exclusion Criteria:

  • Severe obstructive lung disease
  • Angina with minimal exertion
  • Pregnancy
  • Have or have had cancer other than lung cancer
  • Worked in the mining Industry

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02388074


Locations
Layout table for location information
United States, New Mexico
Radiology Associates of Albuquerque (RAA)
Albuquerque, New Mexico, United States, 87109
Sponsors and Collaborators
bioAffinity Technologies Inc.
Radiology Associates of Albuquerque
Investigators
Layout table for investigator information
Principal Investigator: Lara Patriquin, MD Radiology Associates of Albuquerque

Layout table for additonal information
Responsible Party: bioAffinity Technologies Inc.
ClinicalTrials.gov Identifier: NCT02388074     History of Changes
Other Study ID Numbers: MODA-002
First Posted: March 13, 2015    Key Record Dates
Results First Posted: June 17, 2015
Last Update Posted: July 14, 2015
Last Verified: June 2015

Keywords provided by bioAffinity Technologies Inc.:
Lung Cancer
Porphyrin
Fluorescence
Diagnostic
Sputum Cytology
Early Detection

Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases